PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner
PX-12 (1-methylpropyl 2-imidazolyl disulfide) as a thioredoxin (Trx) inhibitor has an anti-tumor effect. However, there is no report about the toxicological effect of PX-12 on lung cancer cells. Here, we investigated the anti-growth effects of PX-12 on Calu-6 lung cancer cells in relation to reactive oxygen species (ROS) and glutathione (GSH) levels. PX-12 induced the growth inhibition of Calu-6 cells with IC50 of nearly 3 μM at 72 h. In contrast, PX-12 did not affect the growth of human small airway epithelial cells (HSAECs). Cell cycle distribution analysis indicated that PX-12 significantly induced a G2/M phase arrest in Calu-6 cells. PX-12 also increased the number of annexin V-FITC-positive cells in Calu-6 cells. All the tested caspase inhibitors markedly prevented Calu-6 cell death induced by PX-12. With regard to ROS and GSH levels, PX-12 increased ROS levels containing O2 ·− in Calu-6 cells and induced the depletion of GSH. N-acetyl cysteine (NAC), which is a well-known antioxidant, significantly reduced O2 ·− level in PX-12-treated Calu-6 cells and prevented apoptosis and GSH depletion in these cells. In conclusion, it is the first report that PX-12 inhibited the growth of Calu-6 cells via a G2/M phase arrest as well as apoptosis, which effect was related to the intracellular increases in ROS levels.
KeywordsPX-12 Reactive oxygen species Thioredoxin Apoptosis Lung cancer
Reactive oxygen species
- MMP (ΔΨm)
Mitochondrial membrane potential
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIP) (No. 2008–0062279) and supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013006279). This paper was supported by research funds of Chonbuk National University in 2014.
Conflicts of interest
- 18.Baker AF, Adab KN, Raghunand N, Chow HH, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T. A phase ib trial of 24-hour intravenous px-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Investig New Drugs. 2012.Google Scholar
- 19.Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, et al. A phase i pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2007;13:2109–14.CrossRefGoogle Scholar
- 27.Harlow E, Lane D: Bradford assay. CSH Protoc. 2006;2006.Google Scholar